ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

N-Methyl-3,4-methylenedioxyamphetamine

Also written as “Midomafetamine HCl”, “Midomafetamine” and “midomafetamine HCl”.

Its studies are mostly in Stress Disorders, Post-Traumatic · Autism Spectrum Disorder · Autistic Disorder · Anxiety Disorders · Binge-Eating Disorder, led by 4 companies.

Drug pageN-Methyl-3,4-methylenedioxyamphetamine: every studyAll 91 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 14, 201829 company-led studies, 2 open or runningNext primary completion: Dec 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Resilient Pharmaceuticalsits history only262 open or runningphase 3since May 14, 2018Aug 24, 2004Dec 2028phase 1 · NCT03606538
Definium Therapeutics US10 open or runningphase 2since Dec 22, 2025Dec 22, 2025none ahead
MAPS Europeits history only10 open or runningphase 2since Jul 19, 2019Jul 19, 2019none ahead
Remedyits history only10 open or runningphase 2since Sep 19, 2021Sep 19, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Definium Therapeutics US only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 22, 2025First study: phase 2 study in Autism Spectrum DisorderFirst studyNCT07303907 · 5 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Definium Therapeutics US leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07303907Autism Spectrum Disorder · United States2CompletedSep 16, 20265

How it is read

Names in the registry

  • “Midomafetamine HCl”, 10 entries
  • “Midomafetamine”, 7 entries
  • “midomafetamine HCl”, 2 entries
  • “MDMA”, 2 entries
  • “midomafetamine”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.